Italia markets closed

Cellular Biomedicine Group, Inc. (CBMG)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
18,41+0,02 (+0,11%)
Alla chiusura: 4:00PM EDT

Cellular Biomedicine Group, Inc.

1345 Avenue of Americas
15th Floor
New York, NY 10105
United States
347 905 5663

Impiegati a tempo pieno217

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Bizuo LiuCEO, CFO & Exec. Director541,33kN/D1965
Dr. Yihong YaoChief Scientific Officer364,98kN/D1968
Mr. Andrew K. ChanChief Legal Officer, Sr. VP of Corp. Devel. & Sec.475,08kN/D1958
Mr. Derrick C. LiHead of Strategy & Investor RelationsN/DN/DN/D
Ms. Sarah KellyDirector of Corp. CommunicationsN/DN/DN/D
Dr. Li ZhangChief Production OfficerN/DN/DN/D
Prof. Zhong Chen KouChief Scientist of ImmunologyN/DN/DN/D
Dr. Xia Meng Ph.D., BSHead of Early Diagnosis & InterventionN/DN/DN/D
Mr. Michael HumphriesHead of Devel. & StrategyN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2019 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.


Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Governance aziendale

L'ISS Governance QualityScore di Cellular Biomedicine Group, Inc. al 6 ottobre 2020 è 6. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 7; diritti degli azionisti: 4; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.